Bioxytran (BIXT) Times Interest Earned (2010 - 2026)
Bioxytran (BIXT) posted Times Interest Earned of -$54.1 for Q1 2026, down 225.38% sequentially from -$16.63 in Q4 2025, and down 227.23% YoY from $42.52 in Q1 2025.
Bioxytran (BIXT) Times Interest Earned (2010 - 2026) Analysis & Trends
Bioxytran has reported Times Interest Earned for 17 years, with the latest figure at -$54.1 in Q1 2026.
- Quarterly Times Interest Earned fell 227.23% year-over-year to -$54.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$23.48 (down 102.8% YoY) and the FY2025 annual result came in at -$0.53, up 26.63% from the prior year.
- Times Interest Earned slipped to -$54.1 in Q1 2026 per BIXT's latest filing, from -$16.63 in the prior quarter.
- Over five years, Times Interest Earned peaked at $23.82 in Q4 2022 and troughed at -$54.1 in Q1 2026.
- A 5-year average of -$12.63 and a median of -$13.58 in 2025 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2022 and 2023: Times Interest Earned surged 4722.24% in 2022, then tumbled 26932.54% in 2023.
- Over 5 years, Times Interest Earned stood at $23.82 in 2022, then sank by 58.95% to $9.78 in 2023, then plunged by 149.7% to -$4.86 in 2024, then sank by 242.2% to -$16.63 in 2025, then sank by 225.38% to -$54.1 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$54.1, -$16.63, and -$13.58 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | -18.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -54.10 |
| Dec 31, 2025 | -16.63 |
| Sep 30, 2025 | -13.58 |
| Jun 30, 2025 | -7.44 |
| Mar 31, 2025 | -16.53 |
| Dec 31, 2024 | -4.86 |
| Sep 30, 2024 | -19.40 |
| Jun 30, 2024 | -30.88 |
| Mar 31, 2024 | -4.76 |
| Dec 31, 2023 | 9.78 |
| Sep 30, 2023 | -20.24 |
| Jun 30, 2023 | -26.79 |
| Mar 31, 2023 | -8.93 |
| Dec 31, 2022 | 23.82 |
| Sep 30, 2022 | 0.08 |
| Jun 30, 2022 | -8.56 |
| Mar 31, 2022 | -15.74 |
| Dec 31, 2021 | -0.52 |
| Sep 30, 2021 | -16.85 |
| Jun 30, 2021 | -12.38 |